Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$4.68
-1.9%
$6.34
$4.45
▼
$25.95
$214.40M1.19715,331 shs479,741 shs
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$6.38
-0.4%
$5.92
$3.63
▼
$8.98
$241.65M0.99283,489 shs242,759 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.28
-3.8%
$1.76
$1.22
▼
$3.90
$65.58M0.71133,955 shs70,762 shs
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
$8.70
-2.2%
$11.51
$2.57
▼
$16.45
$265.50MN/A69,947 shs50,092 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-6.47%-18.74%-4.41%-50.77%-42.18%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
+0.16%0.00%+0.16%+41.59%-15.79%
MediciNova, Inc. stock logo
MNOV
MediciNova
-0.75%-5.67%-5.00%-2.92%-7.64%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
+3.98%-15.89%-17.23%-6.81%+199.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$4.68
-1.9%
$6.34
$4.45
▼
$25.95
$214.40M1.19715,331 shs479,741 shs
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$6.38
-0.4%
$5.92
$3.63
▼
$8.98
$241.65M0.99283,489 shs242,759 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.28
-3.8%
$1.76
$1.22
▼
$3.90
$65.58M0.71133,955 shs70,762 shs
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
$8.70
-2.2%
$11.51
$2.57
▼
$16.45
$265.50MN/A69,947 shs50,092 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-6.47%-18.74%-4.41%-50.77%-42.18%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
+0.16%0.00%+0.16%+41.59%-15.79%
MediciNova, Inc. stock logo
MNOV
MediciNova
-0.75%-5.67%-5.00%-2.92%-7.64%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
+3.98%-15.89%-17.23%-6.81%+199.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
2.63
Moderate Buy$29.00519.53% Upside
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
1.60
Reduce$6.501.96% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
2.71
Moderate Buy$7.75505.94% Upside
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
2.67
Moderate Buy$9.003.51% Upside

Current Analyst Ratings Breakdown

Latest MNOV, TTRX, LFCR, and BIOA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Lower Price TargetBuy$21.00 ➝ $20.00
11/16/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
Reiterated RatingSell (E+)
11/9/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Reiterated RatingBuy
11/6/2026
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
DowngradeHold ➝ Strong Sell
10/26/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
UpgradeSell (E+) ➝ Sell (D-)
10/23/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
UpgradeSell ➝ Hold$10.00
10/16/2026
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
UpgradeSell (E+) ➝ Sell (D-)
10/11/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Initiated CoverageNeutral$8.00
10/11/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
UpgradeHold
10/8/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
DowngradeSell (D-) ➝ Sell (E+)
10/2/2026
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$8.99M23.93N/AN/A$7.54 per share0.62
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$128.87M1.88N/AN/A($1.94) per share-3.29
MediciNova, Inc. stock logo
MNOV
MediciNova
$935.72K70.03N/AN/A$0.80 per share1.60
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/AN/AN/AN/A$0.19 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$80.61M-$2.55N/AN/AN/A-1,253.60%-31.42%-29.59%N/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/A-$1.86N/AN/AN/A-56.80%N/A-29.53%N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
-$12M-$0.21N/AN/AN/A-1,126.60%-26.47%-24.24%N/A
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-$3.19M-$0.43N/AN/AN/AN/A-261.87%-70.18%N/A

Latest MNOV, TTRX, LFCR, and BIOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.0625-$0.06+$0.0025-$0.06$0.05 million$0.14 million
11/9/2026Q3 2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/A-$0.21N/A-$0.21N/AN/A
11/5/2026Q3 2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$0.68-$0.73-$0.05-$0.73N/A$0.30 million
11/4/2026Q1 2027
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$0.2975-$1.08-$0.7825-$1.08$25.57 million$25.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/AN/AN/AN/AN/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
15.51
15.51
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/A
3.84
2.59
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
8.75
8.75
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
1.01
3.19
3.19

Institutional Ownership

CompanyInstitutional Ownership
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
83.36%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
17.55%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
32.68%
MediciNova, Inc. stock logo
MNOV
MediciNova
14.00%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
55.89%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
6245.96 million37.89 millionOptionable
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
38237.91 million25.52 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
651.23 million44.06 millionOptionable
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
230.57 million13.49 millionOptionable

Recent News About These Companies

Turn Therapeutics Inc. GAAP EPS of -$0.21
Turn Therapeutics Inc (TTRX)
Turn Therapeutics Inc.(NasdaqGM:TTRX) added to S&P TMI Index
Turn Therapeutics Inc. GAAP EPS of -$0.20

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAge Labs stock logo

BioAge Labs NASDAQ:BIOA

$4.68 -0.09 (-1.87%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Lifecore Biomedical stock logo

Lifecore Biomedical NASDAQ:LFCR

$6.38 -0.03 (-0.39%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.28 -0.05 (-3.83%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Turn Therapeutics stock logo

Turn Therapeutics NASDAQ:TTRX

$8.70 -0.20 (-2.19%)
As of 02:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.